SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

NCT05568680 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Cholangiocarcinoma Recurrent
Mesothelioma, Malignant

Interventions

BIOLOGICAL: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR

Sponsor

Verismo Therapeutics